Physician profile
Patrick A Janson
NPI 1366415663
$3,048.70
in general payments reported to CMS, 2019-2025
25 companies · $504 in 2025
The $504 reported for 2025 was more than what 77% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $304 · 2021: $348 · 2022: $546 · 2023: $467 · 2024: $436 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,381.53 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $391.52 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $390.38 | 2020-2025 | Acthar |
| Lombart Brothers, INC. | $311.45 | 2019-2020 | |
| Allergan, INC. | $308.74 | 2019-2022 | |
| Alcon Vision LLC | $199.11 | 2021-2025 | Tryptyr, Rocklatan |
| Aerie Pharmaceuticals, INC. | $171.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $168.95 | 2019-2023 | |
| Dompe US, INC. | $151.43 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $122.07 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $120.02 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $85.72 | 2022-2023 | Vyzulta, Miebo |
| Amgen INC. | $70.57 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $68.21 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $64.64 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $59.91 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $57.36 | 2019 | |
| Biotissue Holdings INC. | $56.33 | 2023-2024 | |
| Glaukos Corporation | $51.64 | 2022-2025 | Idosetr |
| Rxsight INC | $50.59 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Harrow Eye, LLC | $41.64 | 2024-2025 | Vevye |
| Ani Pharmaceuticals, INC. | $30.55 | 2023 | Purified Cortrophin Gel |
| Shire North American Group INC | $27.79 | 2019 | |
| Thea Pharma INC. | $21.07 | 2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $14.82 | 2025 | Dextenza |
| Ivantis, INC | $13.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Janson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.